Related Experiment Video
Updated: Aug 5, 2026
09:57
Passive Administration of Monoclonal Antibodies Against H. capsulatum and Others Fungal Pathogens
Published on: February 14, 2011
Targeted prophylaxis with amphotericin B lipid complex in liver transplantation
Summary
Amphotericin B lipid complex prophylaxis effectively prevented invasive fungal infections (IFI) in high-risk liver transplant recipients. This antifungal strategy was well-tolerated across multiple dosages, with the lowest dose recommended for ongoing use.
Area of Science:
- Transplantation Medicine
- Infectious Diseases
- Pharmacology
Background:
- Liver transplant recipients requiring prolonged intensive care unit (ICU) stay are at high risk for invasive fungal infections (IFI).
- Prophylaxis strategies are crucial for preventing IFI in this vulnerable population.
Purpose of the Study:
- To prospectively evaluate the safety and efficacy of amphotericin B lipid complex prophylaxis in liver transplant recipients at high risk for IFI.
- To determine the optimal dosage of amphotericin B lipid complex for antifungal prophylaxis in this patient group.
Main Methods:
- A prospective study involving 30 high-risk liver transplant recipients (defined by >=5 days ICU stay).
- Patients received amphotericin B lipid complex prophylaxis at decreasing dosages (5 mg/kg/d, 2.5 mg/kg/d, 1 mg/kg/d).
- Safety, efficacy, and fungal colonization were assessed throughout the prophylaxis period.
Main Results:
- No patients developed proven invasive fungal infections (IFI) while receiving prophylaxis.
- All fungal isolates were susceptible to amphotericin B in vitro.
- Amphotericin B lipid complex was well-tolerated, with no attributed deaths, serious adverse reactions, or nephrotoxicity.
Conclusions:
- Targeted prophylaxis with amphotericin B lipid complex is a safe and effective strategy for preventing IFI in liver transplant recipients requiring prolonged ICU care.
- The recommended prophylactic dose is 1 mg/kg/d of amphotericin B lipid complex for this high-risk group.
Related Concept Videos
01:27Cryptococcal Meningitis
Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
01:15Antifungal Agents
Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...